Synairgen plc (LON:SNG – Get Rating)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 13 ($0.16) and traded as low as GBX 8.25 ($0.10). Synairgen shares last traded at GBX 9 ($0.11), with a volume of 419,796 shares trading hands.
Synairgen Stock Down 2.3 %
The business’s 50 day simple moving average is GBX 9.77 and its 200-day simple moving average is GBX 12.87. The company has a market cap of £16.92 million, a price-to-earnings ratio of -93.33 and a beta of -2.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 7.19.
Synairgen Company Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.